174 related articles for article (PubMed ID: 34702115)
21. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry.
Amador C; Greiner TC; Heavican TB; Smith LM; Galvis KT; Lone W; Bouska A; D'Amore F; Pedersen MB; Pileri S; Agostinelli C; Feldman AL; Rosenwald A; Ott G; Mottok A; Savage KJ; de Leval L; Gaulard P; Lim ST; Ong CK; Ondrejka SL; Song J; Campo E; Jaffe ES; Staudt LM; Rimsza LM; Vose J; Weisenburger DD; Chan WC; Iqbal J
Blood; 2019 Dec; 134(24):2159-2170. PubMed ID: 31562134
[TBL] [Abstract][Full Text] [Related]
22. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martín García-Sancho A; Rodríguez-Pinilla SM; Domingo-Domenech E; Climent F; Sánchez-Garcia J; López Jiménez J; García-Cosío Piqueras M; Castellvi J; González AJ; González de Villambrosia S; Gómez Codina J; Navarro B; Rodríguez G; Borrero JJ; Fraga M; Naves A; Baeza L; Córdoba R
Br J Haematol; 2023 Oct; 203(2):182-193. PubMed ID: 37386897
[TBL] [Abstract][Full Text] [Related]
23. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
24.
Maura F; Dodero A; Carniti C; Bolli N; Magni M; Monti V; Cabras A; Leongamornlert D; Abascal F; Diamond B; Rodriguez-Martin B; Zamora J; Butler A; Martincorena I; Tubio JMC; Campbell PJ; Chiappella A; Pruneri G; Corradini P
Haematologica; 2021 Nov; 106(11):2918-2926. PubMed ID: 33054126
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous peripheral T-cell lymphoma, not otherwise specified: A single-center prognostic analysis.
Tolkachjov SN; Weenig RH; Comfere NI
J Am Acad Dermatol; 2016 Nov; 75(5):992-999. PubMed ID: 27498959
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
27. 25-Hydroxy vitamin D deficiency is an inferior predictor of peripheral T-cell lymphomas.
Shen HR; Tang J; Li WY; Liang JH; Li Y; Wu JZ; Wang L; Li JY; Gao R; Yin H; Xu W
Ann Hematol; 2024 Feb; 103(2):565-574. PubMed ID: 37951853
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.
Zhang H; Lv H; Jia X; Hu G; Kong L; Zhang T; Li L; Pan Y; Zhai Q; Meng B; Wang X; Wang H; Wang X
Oncol Lett; 2019 Aug; 18(2):1415-1423. PubMed ID: 31423206
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.
Chen Y; Neelapu S; Feng L; Bi W; Yang TH; Wang M; Fanale MA; Westin JR; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Fowler NH; McLaughlin P; Cabanillas F; Oki Y; Nastoupil LJ; Rodriguez A
Br J Haematol; 2016 Oct; 175(2):290-299. PubMed ID: 27448187
[TBL] [Abstract][Full Text] [Related]
30. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
[TBL] [Abstract][Full Text] [Related]
31. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.
Bhatt VR; Giri S; Verma V; Manandhar S; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):373-8. PubMed ID: 27349764
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of POD24 in peripheral T-cell lymphoma.
Chen H; Ma R; Zhang Q; Lu F; Ma Y; Zhou J; Cao J; Qi K; Yan Z; Sang W; Zhu F; Sun H; Li D; Li Z; Cheng H; Xu K; Chen W
Hematology; 2024 Dec; 29(1):2304483. PubMed ID: 38251872
[TBL] [Abstract][Full Text] [Related]
33. A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK.
Kang S; Cho H; Kim S; Lee K; Kang EH; Park JS; Lee YS; Park CS; Go H; Huh J; Ryu JS; Lee SW; Kim SJ; Kim WS; Yoon SE; Ko YH; Suh C
Cancer Res Treat; 2023 Jan; 55(1):314-324. PubMed ID: 35381163
[TBL] [Abstract][Full Text] [Related]
34. Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS).
Oluwasanjo A; Kartan S; Johnson W; Alpdogan O; Gru A; Mishra A; Haverkos BM; Gong J; Porcu P
Cancer Treat Res; 2019; 176():83-98. PubMed ID: 30596214
[TBL] [Abstract][Full Text] [Related]
35. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
37. Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry.
Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
Ann Hematol; 2021 Jan; 100(1):157-165. PubMed ID: 33089366
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
40. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified.
Ludvigsen M; Bjerregård Pedersen M; Lystlund Lauridsen K; Svenstrup Poulsen T; Hamilton-Dutoit SJ; Besenbacher S; Bendix K; Møller MB; Nørgaard P; d'Amore F; Honoré B
Blood Adv; 2018 Oct; 2(19):2533-2542. PubMed ID: 30291111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
